BTIG initiated coverage of BioAge Labs (BIOA) with a Buy rating and $40 price target BioAge is a clinical-stage biopharmaceutical company focused on treating disease related to human aging, the analyst tells investors in a research note. The firm says the company mines human datasets to identify proteins and genetic elements whose trajectories in early adulthood predict lifelong outcomes. It has a four-year cash runway with catalysts for BGE-102 in the second half of 2026 and for BGE-105 in mid-2027, BTIG notes. The firm believes BioAge’s lead program in cardiovascular risk “seems biologically de-risked” based on readouts linking reductions in systemic inflammation to improved outcomes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
- BioAge Labs reports Q1 EPS (52c), consensus (63c)
- BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating
- BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
- BioAge Labs initiated with a Buy at Needham